The investigational mRNA vaccine is also well tolerated, according to trial led by Kaiser Permanente Washington researcher and others.
Can lessons from Immunity Community help build acceptance of COVID-19 vaccines? Clarissa Hsu, PhD, thinks so.
How Paula Blasi brings research findings to light to support Kaiser Permanente’s rapid response to COVID-19
National Institute of Allergy and Infectious Diseases-sponsored phase 1 trial tested mRNA vaccine.
Dr. Mike Jackson has long studied the spread of flu and effectiveness of vaccination at Kaiser Permanente Washington. And now… of COVID-19 too.
Older people must guard against social isolation, as well as COVID-19, to stay well and thrive, writes Dr. Eric B. Larson.
Melissa Parson shares 4 lessons she learned while on assignment with Kaiser Permanente Washington diabetes nurses.